title: Cardiogenic shock.
abstract: The syndrome of cardiogenic shock (CS) comprises a constellation of symptoms and signs that define a subset of patients with inadequate tissue perfusion secondary to myocardial dysfunction. Careful attention to and rapid identification of patients at risk for the development of CS and those with impending CS by both hospitalists and subspecialists will help to implement the time-sensitive therapy that it requires. Physicians should gain a familiarity with the underlying pathophysiology of CS and available diagnostic tools as well as the importance of vasopressor therapy, inotropic therapy, rapid reperfusion therapy, and mechanical support.
authors.affiliation: Cooper University Hospital, Camden, NJ 08103, USA.
authors.forename: Nitasha
authors.initials: N
authors.lastname: Sarswat
authors.forename: Steven M
authors.initials: SM
authors.lastname: Hollenberg
mesh_terms: D000465:Algorithms; D015906:Angioplasty, Balloon, Coronary; D006328:Cardiac Catheterization; D002316:Cardiotonic Agents / Q000627:therapeutic use; D015984:Causality; D001026:Coronary Artery Bypass; D003663:Decision Trees; D003937:Diagnosis, Differential; D004232:Diuretics / Q000627:therapeutic use; D004452:Echocardiography; D004562:Electrocardiography; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006353:Heart-Assist Devices; D017052:Hospital Mortality; D006801:Humans; D007423:Intra-Aortic Balloon Pumping; D011379:Prognosis; D012770:Shock, Cardiogenic / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
chemical_list: D002316:Cardiotonic Agents; D004232:Diuretics; D005343:Fibrinolytic Agents; D014662:Vasoconstrictor Agents